CN Mobile Logo

Search form


Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies

Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies

PITTSBURGH--Nearly three years after it began its investigation, the federal Office of Research Integrity (ORI) has cleared Dr. Bernard Fisher of any scientific misconduct, stating that he did not include false data in his NSABP reports.

"Although I am pleased to get out a little bit from the cloud that I was under, the real harm that was done is more pervasive," Dr. Fisher said in an interview with Oncology News International. "Millions of dollars of taxpayer's money were spent on this investigation that could have been put into research."

As a result of the charges, ongoing NSABP trials were put on hold, including the tamoxifen prevention study, "and women with breast cancer will pay the price in the next few years," Dr. Fisher said. Perhaps most important, he added, the publicity caused women needless worry about their choice of lumpectomy plus radiation over mastectomy.

This "bizarre story of government and politics run amok," as Fisher describes it, began in 1991 when he notified the NCI of fraudulent data from St. Luc Hospital in Montreal. In keeping with the "intent to treat" principle, the patients from St. Luc were included in the final analysis of the affected NSABP studies, including the landmark lumpectomy study. "It must be emphasized that falsified data were not included in any publications," Dr. Fisher said.

On March 13, 1994, an article in the Chicago Tribune appeared, accusing Dr. Fisher of knowingly including false data in his reports; this spurred Rep. John Dingell (D-Mich) to initiate a Congressional hearing on the issue.

Under pressure from Congress, the NCI ordered the ORI investigation, and the University of Pittsburgh, in turn, removed Dr. Fisher from his posts as director and principal investigator of the NSABP. (He is currently Distinguished Service Professor in the Department of Surgery at the University of Pittsburgh School of Medicine.)

Dr. Fisher has filed suit against the NIH, NCI, ORI, and the University of Pittsburgh seeking full reinstatement and unspecified damages. The main issue, he said, is the lack of due process in the investigation. "During three years of investigations, no one from the ORI, NCI, or University of Pittsburgh ever spoke to me or gave me a chance to speak."

The suit also alleges violations of Dr. Fisher's first amendment rights in terms of academic freedom and freedom of speech. "I was being told where to publish and what to publish, and my papers were subjected to prepublication reviews," he said. "I am taking a stand so that this will not happen to other scientists in the future."

Finally, the suit is about his desire to be back at his work with restored responsibility and renewed vigor. "Women are still dying of breast cancer, and as long as I have the ability to work, I want to continue to do research in this field."

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.